Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)

This is a Phase II clinical study for people with stage IV cancer. The study will evaluate the use of stereotactic body radiation therapy (SBRT), a type of focused radiation treatment, together with immunotherapy-based treatment. SRBT will be used to treat multiple areas of cancer that have spread to other parts of the body. The study will evaluate whether this treatment approach can be safely given while patients continue their planned cancer treatment and may help control their cancer.

Trial Details

NCT ID
NCT07770100
Phase
PHASE2
Sponsor
Mark Bernard
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Stereotactic Body Radiation Therapy (SBRT)
  • Pembrolizumab
  • Nivolumab
  • Atezolizumab
  • Ipilimumab
Locations (sample)
  • Lexington, Kentucky, United States|37.98869,-84.47772

Key Eligibility Criteria

  • Histologically proven advanced or stage IV head \& neck, non-small cell lung cancer, cervical, esophageal, gastric, and gastroesophageal cancer at …
  • At least 6 metastases eligible for SBRT comprising: lung, liver, adrenal glands, bone, and lymph node sites
  • The 1 irradiated lesion must have a max point dose of 5Gy or less.
  • Eligible for Immunotherapy for an FDA-approved indication as defined in section 6.1. NOTE: No limit is placed on prior systemic treatment unless it…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →